Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules

Background. Thyroid nodule (TN) is a common thyroid disease worldwide, and it has increased significantly last decades. Most TNs are usually incidental findings of asymptomatic, benign lesions discovered by imaging modalities performed for reasons unrelated to thyroid diseases. The purpose of this s...

Full description

Bibliographic Details
Main Authors: Gulhan Duman, Baris Sariakcali
Format: Article
Language:English
Published: Publishing House Zaslavsky 2021-05-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
Online Access:http://iej.zaslavsky.com.ua/article/view/232652
id doaj-a47a10871cf3496eb0fe1a94d31c96fb
record_format Article
spelling doaj-a47a10871cf3496eb0fe1a94d31c96fb2021-07-06T10:34:21ZengPublishing House ZaslavskyMìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272021-05-0117322623310.22141/2224-0721.17.3.2021.232652270285Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodulesGulhan Duman0https://orcid.org/0000-0002-4057-5701Baris Sariakcali1https://orcid.org/0000-0001-5133-1318Division of Endocrinology and Metabolism, Department of Internal Medicine, Cumhuriyet University, Faculty of Medicine, Sivas, TurkeyDivision of Endocrinology and Metabolism, Department of Internal Medicine, Cumhuriyet University, Faculty of Medicine, Sivas, TurkeyBackground. Thyroid nodule (TN) is a common thyroid disease worldwide, and it has increased significantly last decades. Most TNs are usually incidental findings of asymptomatic, benign lesions discovered by imaging modalities performed for reasons unrelated to thyroid diseases. The purpose of this study was to investigate the value of serum WNT-induced secreted protein 1 (WISP1) level as a supporting biomarker to perform differential diagnosis of benign and non-benign thyroid nodules. Materials and methods. The study was completed with the 89 patients undergone fine needle aspiration biopsy and 43 controls. The patients were composed of 96 (72.7 %) females and 36 (27.3 %) males. And they were divided into 2 group according to the Bethesda cytological evaluation as Benign (Bethesda 2) and Non-Benign (Bethesda 3–6) groups. Their serum WISP1 levels were measured by an ELISA method. Results. There were 58 (43.9 %) patients in Benign (Bethesda 2) and 31 (23.5 %) in non-Benign (Bethesda 3–6) groups. In the contrary nodule size was bigger in the Non-benign group than that benign group (p = 0.006). The serum WISP1 level in the Benign (Bethesda 2) group was significantly higher than that in the and Non-Benign (Bethesda 3–6) group, and controls (p < 0). The difference between benign and non-benign group accordingly to their echogenicitiy was significant (p < 0.05). In benign group there was 76.9 % mixed echoic nodules, 76.7 % isoechoic nodules 68.4 % isohypoechoic nodules and 35.7 % hypoechoic nodules. In the non-benign group, the highest hypoechoic echo (64.3 %), the least mixed echo (23.1 %), while in the benign group, the most mixed echo (76.9 %), the least hypoechoic echo (35.7 %) was present. There was no relation between WISP1 levels and echogenicity with Kruskal-Wallis H test. Conclusions. According to the preliminary results of current study, addition of serum WISP1 measurement to the differential diagnostic work-up of thyroid nodules patients may provide supportive information. In thyroid nodules patients with Benign (Bethesda 2) category of cytological evaluation, a higher level of serum WISP1 may support cytological diagnosis.http://iej.zaslavsky.com.ua/article/view/232652thyroid nodule, thyroid ultrasonography, fine-needle aspiration biopsy, wisp1
collection DOAJ
language English
format Article
sources DOAJ
author Gulhan Duman
Baris Sariakcali
spellingShingle Gulhan Duman
Baris Sariakcali
Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
Mìžnarodnij Endokrinologìčnij Žurnal
thyroid nodule, thyroid ultrasonography, fine-needle aspiration biopsy, wisp1
author_facet Gulhan Duman
Baris Sariakcali
author_sort Gulhan Duman
title Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
title_short Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
title_full Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
title_fullStr Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
title_full_unstemmed Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules
title_sort serum wnt-induced secreted protein 1 level as a potential biomarker for thyroid nodules
publisher Publishing House Zaslavsky
series Mìžnarodnij Endokrinologìčnij Žurnal
issn 2224-0721
2307-1427
publishDate 2021-05-01
description Background. Thyroid nodule (TN) is a common thyroid disease worldwide, and it has increased significantly last decades. Most TNs are usually incidental findings of asymptomatic, benign lesions discovered by imaging modalities performed for reasons unrelated to thyroid diseases. The purpose of this study was to investigate the value of serum WNT-induced secreted protein 1 (WISP1) level as a supporting biomarker to perform differential diagnosis of benign and non-benign thyroid nodules. Materials and methods. The study was completed with the 89 patients undergone fine needle aspiration biopsy and 43 controls. The patients were composed of 96 (72.7 %) females and 36 (27.3 %) males. And they were divided into 2 group according to the Bethesda cytological evaluation as Benign (Bethesda 2) and Non-Benign (Bethesda 3–6) groups. Their serum WISP1 levels were measured by an ELISA method. Results. There were 58 (43.9 %) patients in Benign (Bethesda 2) and 31 (23.5 %) in non-Benign (Bethesda 3–6) groups. In the contrary nodule size was bigger in the Non-benign group than that benign group (p = 0.006). The serum WISP1 level in the Benign (Bethesda 2) group was significantly higher than that in the and Non-Benign (Bethesda 3–6) group, and controls (p < 0). The difference between benign and non-benign group accordingly to their echogenicitiy was significant (p < 0.05). In benign group there was 76.9 % mixed echoic nodules, 76.7 % isoechoic nodules 68.4 % isohypoechoic nodules and 35.7 % hypoechoic nodules. In the non-benign group, the highest hypoechoic echo (64.3 %), the least mixed echo (23.1 %), while in the benign group, the most mixed echo (76.9 %), the least hypoechoic echo (35.7 %) was present. There was no relation between WISP1 levels and echogenicity with Kruskal-Wallis H test. Conclusions. According to the preliminary results of current study, addition of serum WISP1 measurement to the differential diagnostic work-up of thyroid nodules patients may provide supportive information. In thyroid nodules patients with Benign (Bethesda 2) category of cytological evaluation, a higher level of serum WISP1 may support cytological diagnosis.
topic thyroid nodule, thyroid ultrasonography, fine-needle aspiration biopsy, wisp1
url http://iej.zaslavsky.com.ua/article/view/232652
work_keys_str_mv AT gulhanduman serumwntinducedsecretedprotein1levelasapotentialbiomarkerforthyroidnodules
AT barissariakcali serumwntinducedsecretedprotein1levelasapotentialbiomarkerforthyroidnodules
_version_ 1721317788337831936